3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EON Resources said an error in its depletion, depreciation and amortization expense for 2025 overstated that expense, so its 2025 Form 10-K filed September 28, 2026 should no longer be relied upon. The company expects to file an amended 10-K showing the loss attributable to shareholders falling from $10.1 million to about $7.5 million, but the change is non-cash and the figures remain preliminary pending audit completion.
Depletion, depreciation and amortization expense for fiscal 2025 was overstated by $3,540,000, and the net loss decreased by $2,632,000.
Loss attributable to EON Resources shareholders for 2025 is expected to be reduced from $10.1 million to approximately $7.5 million.
Management determined on October 8, 2026 that the 2025 Form 10-K should no longer be relied upon.
The restatement has no impact on cash flows or cash, cash equivalents and marketable investments; figures remain subject to audit and review, which the company discussed with CBIZ CPAs P.C.
Sunshine Biopharma (SBFM) closed a best-efforts public offering on October 9, 2026, with gross proceeds of approximately $6.0 million before placement agent fees and other expenses. The offering included Series D warrants with a $0.66 exercise price, which the company says could bring up to about $14.4 million more if fully exercised, though no assurance is given that any warrants will be exercised.
Common units sold at $0.55 each, with each unit including one share of common stock and two Series D warrants exercisable at $0.66 per share over five years.
Placement agent Aegis Capital Corp. received a 7% fee on the public offering price plus a 1% non-accountable expense allowance.
The company expects to use net proceeds for general corporate purposes and working capital.
The offering was made under a Form S-1 (File No. 333-299274) declared effective on October 7, 2026.
SolarMax Technology reported second quarter 2026 results, with revenue up 49% to $10.2 million and gross profit up to $2.4 million from $605,000 a year earlier. The net loss widened to $4.7 million, or $0.98 per share, from $1.9 million, or $0.50 per share, mainly because of a one-time $4.3 million legal judgment expense tied to its China segment. Shareholders see higher sales and gross profit offset by a larger loss in the period.
Revenue of $10.2 million in Q2 2026, up 49% from $6.9 million in Q2 2025
Gross profit of $2.4 million, up 299% from $605,000 in Q2 2025
Total operating expense of $6.9 million, including a $4.3 million legal judgment related to the China segment
Net loss of $4.7 million, or $0.98 per share, versus $1.9 million, or $0.50 per share, a year earlier
Vivakor, Inc. announced a non-binding Letter of Intent to acquire 100% of Direct Midstream, LLC, a Midland, Texas water midstream company, at a gross purchase price of $40 million. The deal remains subject to due diligence, audited financial statements, a fairness opinion, and a definitive agreement, and the company says there is no assurance it will be completed. The filing also disclosed conversion of $350,000 of a junior secured note into 128,965 common shares.
Gross purchase price of $40 million, based on four times Direct Midstream's targeted 2027 free cash flow of $10 million
At closing, Vivakor would invest $10 million in Direct Midstream, reducing the consideration payable dollar-for-dollar
Remaining consideration would be about $29 million of Series B Preferred Stock and $1 million of common stock, before debt or working capital adjustments
Between October 5 and October 6, 2026, J.J. Astor converted $350,000 of its Second Note into 128,965 common shares
Sound Point Meridian Capital, Inc. estimated its unaudited net asset value per share at $9.04 to $9.14 as of September 30, 2026. For the quarter ended September 30, 2026, it estimated net investment income of $0.24 to $0.32 per share and a realized loss of $0.68 to $0.60 per share. The realized loss is larger than the estimated net investment income, so shareholders face a mixed picture for the quarter.
Estimated net asset value per share as of September 30, 2026: $9.04 to $9.14
Estimated net investment income for the quarter: $0.24 to $0.32 per share
Estimated realized loss for the quarter: $0.68 to $0.60 per share
Quantum Corporation terminated Chief Financial Officer William H. White effective October 9, 2026, and appointed Chief Accounting Officer Hiral A. Patel as Principal Financial Officer the same day. The company said it is early in its closing process for the quarter ended September 30, 2026, but expects to meet or exceed its previously issued guidance, a view subject to completion of closing procedures and audit review. The filing does not state a reason for the termination.
William H. White terminated as CFO and principal financial officer effective October 9, 2026; the company says no disruption to operations is expected
Hiral A. Patel, Chief Accounting Officer since September 1, 2026, appointed Principal Financial Officer effective October 9, 2026
Company expects to meet or exceed guidance for the quarter ended September 30, 2026, but results remain subject to closing and auditor review
Company expects to timely file its Form 10-Q for the quarter ended September 30, 2026
Shareholders approved an amendment extending the company's deadline to complete a business combination from October 9, 2026 to April 9, 2027, in monthly steps up to six times or an earlier date set by the board. Holders of 18,322,071 public shares redeemed for about $198.6 million, about $10.84 per share, leaving 4,677,929 public shares outstanding.
Shareholders approved extending the business combination deadline from October 9, 2026 to April 9, 2027, in monthly steps up to six times.
Holders of 18,322,071 Class A public shares redeemed for about $198.6 million, about $10.84 per share.
Investors holding 4,481,851 Class A shares agreed not to redeem and to vote for the extension; the sponsor will transfer 256,061 Class A shares to them per extension month at the closing of an initial business combination.
Shareholders also ratified WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026, with 23,647,778 votes for.
Evernorth Holdings, formerly the Armada Acquisition Corp II SPAC, closed its business combination with Ripple's XRP contribution on October 9, 2026, making Pubco the successor registrant. Holders of 18,463,753 public shares redeemed for about $193.6 million, and the filing's pro forma figures show a $264.1 million digital assets impairment for the six months ended June 30, 2026, which weighs on the combined company's results.
Closing took place October 9, 2026; 4,536,247 public shares remained outstanding and about $47.6 million was released from the trust account.
Public share holders redeemed 18,463,753 shares for about $193.6 million, or about $10.49 per share.
Ripple contributed 126,791,458 XRP tokens; the Closing XRP Price of $1.43069 was below the $2.36609 signing price, and amended agreements reduced the shares issuable to investors.
Pro forma digital assets impairment was $264.1 million and pro forma net loss attributable to the parent was $268.7 million for the six months ended June 30, 2026; lock-ups last six months after closing.
DENTSPLY SIRONA obtained lender consent and amended its revolving credit facility and three note purchase agreements, effective around September 30, 2026. The changes raise the maximum permitted leverage ratios for the quarters ending September 30 and December 31, 2026, and add tighter limits on new liens, subsidiary debt and restricted payments. The company says the revised terms are intended to keep it in compliance with its debt covenants in all material respects.
Maximum permitted Total Leverage Ratio and Senior Leverage Ratio increased for fiscal quarters ending September 30, 2026 and December 31, 2026.
Until the compliance certificate for fiscal 2026 is delivered, new liens and new subsidiary debt are generally prohibited, and restricted payments are limited with certain carveouts.
Credit facility adds a new pricing level for the applicable margin and facility fee; note interest increases if leverage meets specified thresholds.
Mangoceuticals sold 657,000 shares of common stock, each paired with a warrant, in a registered direct offering to certain investors, for gross proceeds of about $492,750, with closing on October 9, 2026. The unit price was a 74% premium to the referenced recent closing price of $0.43, but the warrants can add up to 788,400 shares and may dilute existing shareholders.
657,000 shares sold at $0.75 per share and accompanying warrant, for gross proceeds of about $492,750 before offering expenses
Warrants exercisable at $1.00 per share, immediately exercisable, expiring five years from issuance, covering up to 788,400 shares
Unit price represents an approximately 74% premium to the referenced recent closing share price of $0.43; no placement agent was engaged
Proceeds intended for working capital and general corporate purposes; separate $2.5 million MangoRx IP subsidiary investment does not involve parent-company shares
Art's-Way Manufacturing reported third-quarter fiscal 2026 sales of $5,615,000, down from $6,432,000, and a net loss of $140,000, compared with net income of $254,000 a year earlier. For the first nine months, sales rose to $20,110,000 from $17,910,000, but net income fell to $230,000 from $1,680,000, and nine-month EPS dropped to $0.04 from $0.33. The company also took a $956,000 term loan from Bank Midwest to buy a new fiberoptic laser and crane system.
Q3 (three months ended August 31, 2026): sales $5,615,000 vs. $6,432,000; net loss $140,000 vs. net income $254,000; EPS $(0.03) vs. $0.05
Nine months ended August 31, 2026: sales $20,110,000 vs. $17,910,000; net income $230,000 vs. $1,680,000; EPS $0.04 vs. $0.33
Management cited rising material and operating costs pressuring margins, and a prior-year Employee Retention Credit that did not repeat in fiscal 2026
Laser Loan of $956,000 dated October 5, 2026; 6.65% fixed for the first 60 payments, then 1-month SOFR plus 3.1%; initial monthly payment $8,456
Delta reported September quarter 2026 results, with adjusted operating revenue up 16% to $17.6 billion, while GAAP net income fell 47% to $756 million. The company gave full-year 2026 EPS guidance of $5.10 to $5.60 and December quarter EPS guidance of $1.15 to $1.65, which matter to shareholders because the GAAP profit decline and the fuel cost pressure both weigh on near-term earnings.
Adjusted operating revenue of $17.6 billion, up 16% year over year; GAAP operating revenue of $20.2 billion, up 21%
GAAP diluted EPS of $1.15 versus $2.17 a year earlier; adjusted diluted EPS of $1.72 versus $1.70
Full-year 2026 EPS outlook of $5.10 to $5.60 and free cash flow of approximately $2.5 billion; December quarter EPS outlook of $1.15 to $1.65
Average fuel price of $3.80 per gallon GAAP, up 68% year over year; free cash flow was $463 million in the September quarter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.